State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, People's Republic of China.
Beijing Tang Yi Hui Kang Biomedical Technology Co., LTD, Beijing, 100032, People's Republic of China.
Stem Cell Res Ther. 2023 Oct 4;14(1):284. doi: 10.1186/s13287-023-03514-1.
Human umbilical cord mesenchymal stem cells (hUC-MSCs) are widely used in cell therapy due to their robust immunomodulatory and tissue regenerative capabilities. Currently, the predominant method for obtaining hUC-MSCs for clinical use is through planar culture expansion, which presents several limitations. Specifically, continuous cell passaging can lead to cellular aging, susceptibility to contamination, and an absence of process monitoring and control, among other limitations. To overcome these challenges, the technology of microcarrier-bioreactor culture was developed with the aim of ensuring the therapeutic efficacy of cells while enabling large-scale expansion to meet clinical requirements. However, there is still a knowledge gap regarding the comparison of biological differences in cells obtained through different culture methods.
We developed a culture process for hUC-MSCs using self-made microcarrier and stirred bioreactor. This study systematically compares the biological properties of hUC-MSCs amplified through planar culture and microcarrier-bioreactor systems. Additionally, RNA-seq was employed to compare the differences in gene expression profiles between the two cultures, facilitating the identification of pathways and genes associated with cell aging.
The findings revealed that hUC-MSCs expanded on microcarriers exhibited a lower degree of cellular aging compared to those expanded through planar culture. Additionally, these microcarrier-expanded hUC-MSCs showed an enhanced proliferation capacity and a reduced number of cells in the cell cycle retardation period. Moreover, bioreactor-cultured cells differ significantly from planar cultures in the expression of genes associated with the cytoskeleton and extracellular matrix.
The results of this study demonstrate that our microcarrier-bioreactor culture method enhances the proliferation efficiency of hUC-MSCs. Moreover, this culture method exhibits the potential to delay the process of cell aging while preserving the essential stem cell properties of hUC-MSCs.
人脐带间充质干细胞(hUC-MSCs)因其强大的免疫调节和组织再生能力而广泛应用于细胞治疗。目前,获得 hUC-MSCs 用于临床应用的主要方法是通过平面培养扩增,该方法存在几个局限性。具体来说,连续的细胞传代会导致细胞老化、易受污染以及缺乏过程监测和控制等问题。为了克服这些挑战,开发了微载体-生物反应器培养技术,旨在确保细胞的治疗功效,同时能够进行大规模扩增以满足临床需求。然而,对于通过不同培养方法获得的细胞的生物学差异比较,仍存在知识空白。
我们开发了一种使用自制微载体和搅拌生物反应器的 hUC-MSCs 培养工艺。本研究系统比较了通过平面培养和微载体-生物反应器系统扩增的 hUC-MSCs 的生物学特性。此外,还采用 RNA-seq 比较了两种培养方式下基因表达谱的差异,有助于鉴定与细胞衰老相关的通路和基因。
研究结果表明,与通过平面培养扩增的细胞相比,在微载体上扩增的 hUC-MSCs 细胞衰老程度较低。此外,这些微载体扩增的 hUC-MSCs 表现出增强的增殖能力和细胞周期阻滞期的细胞数量减少。此外,生物反应器培养的细胞与平面培养的细胞在与细胞骨架和细胞外基质相关的基因表达上存在显著差异。
本研究结果表明,我们的微载体-生物反应器培养方法可提高 hUC-MSCs 的增殖效率。此外,这种培养方法具有延缓细胞衰老过程的潜力,同时保留 hUC-MSCs 的重要干细胞特性。